Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) – Pipeline Review, H2 2017’, provides in depth analysis on Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System and Cardiovascular under development targeting Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

The report reviews Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics and enlists all their major and minor projects

The report assesses Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Jiangsu Hengrui Medicine Co Ltd

Jiangsu Nhwa Pharmaceutical Corp Ltd

Paion AG

Pfizer Inc

Primex Pharmaceuticals Oy

Shire Plc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Overview 6

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Companies Involved in Therapeutics Development 18

Jiangsu Hengrui Medicine Co Ltd 18

Jiangsu Nhwa Pharmaceutical Corp Ltd 18

Paion AG 19

Pfizer Inc 19

Primex Pharmaceuticals Oy 20

Shire Plc 20

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Drug Profiles 21

clonazepam - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

EL-001 - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

LASSBio-785 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

LASSBio-786 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

midazolam hydrochloride - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

midazolam hydrochloride - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

midazolam hydrochloride - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

remimazolam - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

remimazolam - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Dormant Products 37

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Discontinued Products 38

Gamma-Aminobutyric Acid Receptor Subunit Gamma 2 (GABA(A) Receptor Subunit Gamma 2 or GABRG2) - Product Development Milestones 39

Featured News & Press Releases 39

Jun 05, 2017: Primex Pharmaceuticals at Euroanesthesia 2017: Next Innovation in the Management of Pediatric Sedation 39

Oct 19, 2016: Positive Remimazolam Phase III Colonoscopy Results Presented at the 2016 American College of Gastroenterology Annual Scientific Meeting 39

Oct 05, 2016: Primex Files for Marketing Authorization for a pediatric sedative medication 41

Sep 22, 2016: PAION: Remimazolam Phase III Colonoscopy Data to Be Presented at the American College of Gastroenterology 2016 Meeting 41

Sep 06, 2016: PAION announces clinical development progress with remimazolam by its Partner Yichang Humanwell in China 42

Sep 01, 2016: Primex Announces Phase II Results of ADV6209 at the 16th World Congress of Anesthesiologists 42

Aug 31, 2016: Primex Pharmaceuticals: Next real innovation in pediatric anesthesia since propofol 43

Jun 19, 2016: Paion Reports Positive Remimazolam Headline Data In Pivotal U.S. Phase III Study In Procedural Sedation For Colonoscopy 43

Apr 11, 2016: Paion Successfully Completes Patient Recruitment In Phase III Study With Remimazolam For Procedural Sedation During Colonoscopy 44

Feb 18, 2016: PAION reports about positive pre-NDA meeting with Japanese authority PMDA 45

Feb 12, 2016: Paion: US-Patent & Trademark Office Grants Substance Patent For Remimazolam Besylate 45

Feb 09, 2016: Paion Discontinues European Remimazolam Phase III Trial In Cardiac Surgery Patients Due To Insufficient Recruitment 46

Dec 01, 2015: PAION Announces Initiation of U.S. Clinical Safety Trial of Remimazolam in High Risk Patients Undergoing Colonoscopy 46

Oct 14, 2015: Paion Receives Positive Feedback From Japanese Authority PMDA About Production Of Remimazolam For Japan 47

Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 47

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 17

Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 18

Pipeline by Jiangsu Nhwa Pharmaceutical Corp Ltd, H2 2017 18

Pipeline by Paion AG, H2 2017 19

Pipeline by Pfizer Inc, H2 2017 19

Pipeline by Primex Pharmaceuticals Oy, H2 2017 20

Pipeline by Shire Plc, H2 2017 20

Dormant Projects, H2 2017 37

Discontinued Products, H2 2017 38

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports